P1049: A Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent Kit D816V Inhibitor, in Adults With Advanced Systemic Mastocytosis (Apex): Methods, Baseline Data, and Early Insights

DeAngelo, D. J., Pullarkat, V., Piris-Villaespesa, M., George, T. I., Patel, J. L., Ustun, C., Bose, P., Heaney, M. L., Pilla, A., Massaro, M., Exter, B., Jolin, H. A., Mikhak, Z., & Tashi, T. (2022). P1049: A Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent Kit D816V Inhibitor, in Adults With Advanced Systemic Mastocytosis (Apex): Methods, Baseline Data, and Early Insights. HemaSphere, 6, 939–940. https://doi.org/10.1097/01.hs9.0000847064.38588.9b

Authors:

Daniel J. DeAngelo

Vinod Pullarkat

Miguel Piris‐Villaespesa

Tracy I. George

Janaki Patel

Celalettin Üstün

P. Bose

Mark Heaney

A. Pilla

M. Massaro

B. Exter